Metrics as of 10/13/2026, 06:34 PM (Berlin time), refresh in progress.
Kyntra Bio Stock
Kyntra Bio, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Thane Wettig
- Employees
- 34
- Market cap
- $24 M
- IPO
- 14/11/2014
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and…
Kyntra Bio stock: price history
1D
-1.1%
1W
+1.5%
1M
-24.1%
6M
-17.9%
YTD
-31.1%
1Y
-44.8%
2Y
-32.3%
5Y
-97.7%
10Y
-98.6%
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~18% stronger price swings than usual
Ask the agents about Kyntra Bio
Analyst assessment of Kyntra Bio
PRICE TARGET LOW
US$28.00
CONSENSUS
US$28.00
MEDIAN
US$28.00
PRICE TARGET HIGH
US$28.00
0
STRONG BUY
5
BUY
8
HOLD
2
SELL
0
STRONG SELL
15
TOTAL · Hold
As of: 01/09/2026
Kyntra Bio stock metrics
P/E
0.1
P/B
-0.81
EV/EBITDA
0.28
RETURN ON EQUITY
-39.7%
NET MARGIN
-812.3%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
88.0%
FLOAT SHARES
3,561,165
AVG. DAILY VOLUME (30D)
25,328
Insider transactions (SEC)
Wettig Thane
DeLucia David
Wettig Thane
DeLucia David
Wettig Thane
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Kyntra Bio stock
What does Kyntra Bio do?
Kyntra Bio, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Thane Wettig, the company employs around 34 people.
The IPO was on 14/11/2014; the stock trades on NASDAQ under the ticker KYNB.
What do analysts say about Kyntra Bio stock?
15 analysts rate the stock, the consensus is Hold (as of 01/09/2026).
The average price target is US$28.00, ranging from US$28.00 to US$28.00, with a median of US$28.00.
This is an external assessment, not a statement by Market Jury.
When does Kyntra Bio report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 18% stronger than usual.
Does Kyntra Bio pay a dividend?
No, Kyntra Bio currently does not pay a dividend.
Which stocks are comparable to Kyntra Bio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Kyntra Bio stock analyzed?
Clicking "Analyze stock" lets five strategies assess Kyntra Bio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.